BISMUTH INDUCED ENCEPHALOPATHY CAUSED BY TRI POTASSIUM DICITRATO BISMUTHATE IN A PATIENT WITH CHRONIC-RENAL-FAILURE

被引：43

作者：

PLAYFORD, RJ

MATTHEWS, CH

CAMPBELL, MJ

DELVES, HT

HLA, KK

HODGSON, HJF

CALAM, J

机构：

[1] SOUTHAMPTON GEN HOSP,DEPT CLIN BIOCHEM,TRACE ELEMENT UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND

[2] HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0HS,ENGLAND

来源：

GUT | 1990年 / 31卷 / 03期

关键词：

D O I：

10.1136/gut.31.3.359

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

A 68 year old man with a creatinine clearance rate of only 15 ml/min took twice the recommended dose of tripotassium dicitrato bismuthate (TDB) as DeNol(TM) liquid; 10 ml qds; a total of 864 mg bismuth daily for two months. Whole blood bismuth concentrations rose to 880 μg/l and he developed global cerebral dysfunction with hallucinations, ataxia, and an abnormal EEG. Renal clearance of bismuth rose from 0.24 to 2.4 ml/min when the heavy metal chelator 2-3 dimercapto-1 propane sulphonic acid (DMPS) was given by mouth. Bismuth was measured by as novel method involving inductively coupled plasma source mass spectrometry. Fifty days after stopping TDB, whole blood bismuth concentrations fell to 46 μg/l and the patient's EEG returned to normal. His mental function also recovered completely. The case serves as a timely reminder that TDB should not be administered to patients with renal disorders, as stated in the data sheet.

引用

页码：359 / 360

页数：2

共 9 条

[1]

DELVES HT, 1988, CHEM BRIT, V24, P1009

[2]

GAVEY CJ, 1989, ALIMENT PHARM THERAP, V3, P21

[3]

MARSHALL BJ, 1987, DIGESTION, V37, P8

[4]

MARTIN DF, 1981, LANCET, V1, P7

[5]

MARTINBOUYER G, 1980, THERAPIE, V35, P307

[6]

MORROW AW, 1973, MED J AUSTRALIA, V1, P912

[7]

NWOKOLO CU, 1989, ALIMENT PHARM THERAP, V3, P29

[8]

VASKENAPOSHIAN H, 1983, ANN REV PHARM TOXICO, V23, P193

[9] NEUROPSYCHIATRIC SYMPTOMS FOLLOWING BISMUTH INTOXICATION [J].

WELLER, MPI .

POSTGRADUATE MEDICAL JOURNAL, 1988, 64 (750) :308-310

← 1 →